EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial

Mark J Bolland iD, Zaynah Nisa, Anna Mellar, Chiara Gasteiger, Veronica Pinel, Borislav Mihov, Sonja Bastin, Andrew Grey iD, Ian R Reid iD, Greg Gamble iD, Anne Horne

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf569 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Mark J Bolland und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Auckland, Auckland 1142, New Zealand. Hauptthemen laut MEDLINE: Zoledronic Acid, Bone Density Conservation Agents, Bone Density, Osteoporotic Fractures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

We recently reported that zoledronate (zol) given once at baseline or twice (every 5 years) reduced fracture risk over 10 years.

Objective

We assessed whether the effects of zol differ over time or across important baseline variables, and how they relate to changes in bone mineral density (BMD) over time.

Methods

A 10-year, prospective, randomized, double-blind, placebo-controlled trial, was conducted at a clinical research center from 2012 to 2023. Participants included 1054 postmenopausal women, aged 50 to 60 years, with BMD T-score at the lumbar spine, femoral neck, or total hip between 0 and −2.5. Intervention included either 5-yearly 5-mg zol (zol-zol), 5-mg zol infusion at baseline and placebo at 5 years (zol-placebo), or 5-yearly placebo (placebo-placebo). Main outcome measures included morphometric vertebral fractures, major osteoporotic, and any fractures.

Results

Morphometric vertebral fractures were not reduced in the years 0 to 5 following zol but were reduced in years 5 to 10 by 58% (95% CI, 21%-77%) (zol-zol) and 57% (21%-77%) (zol-placebo). For any fracture and major osteoporotic fracture, similar temporal patterns were observed. There were no interactions between treatment effect and baseline variables (including age, body mass index, BMD, falls or fracture history, and estimated fracture risk) or between treatment effect and changes in BMD with zol.

Conclusion

Fracture reductions with single-dose or 5-yearly zol appear greater during years 5 to 10 than years 0 to 5. The risk reductions are broadly consistent across this cohort and independent of baseline or change in BMD. This suggests that routine BMD monitoring may not be necessary for low-risk women considering the option of less frequent zol for long-term fracture risk reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidBone Density Conservation AgentsBone DensityOsteoporotic FracturesOsteoporosis, PostmenopausalSpinal FracturesHumansFemaleMiddle AgedDouble-Blind MethodProspective StudiesTreatment OutcomeFollow-Up StudiesDrug Administration Schedule

Stichwörter der Autor:innen

bone mineral densityfracturepostmenopausal womenzoledronate

Substanzen

Zoledronic AcidBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Medicine, University of Auckland, Auckland 1142, New Zealand.
  • Department of Psychology, Stanford University, Stanford, CA 94305-2004, USA.
  • Department of Radiology, Starship Hospital, Auckland 1142, New Zealand.

ORCID-Profile: Mark J Bolland, Andrew Grey, Ian R Reid, Greg Gamble

Förderung

  • HRC

Zitieren

APA

Bolland, M. J., Nisa, Z., Mellar, A., Gasteiger, C., Pinel, V., Mihov, B., Bastin, S., Grey, A., Reid, I. R., Gamble, G., & Horne, A. (2026). Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf569

Vancouver

Bolland MJ, Nisa Z, Mellar A, Gasteiger C, Pinel V, Mihov B, et al. Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf569

BibTeX
@article{Bolland2026,
  author = {Bolland, Mark J and Nisa, Zaynah and Mellar, Anna and Gasteiger, Chiara and Pinel, Veronica and Mihov, Borislav and Bastin, Sonja and Grey, Andrew and Reid, Ian R and Gamble, Greg and Horne, Anne},
  title = {Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf569}
}
Kostenlos starten →